Rozenn N Lemaitre1, Paul N Jensen1, Andrew Hoofnagle2, Barbara McKnight3, Amanda M Fretts4, Irena B King5, David S Siscovick6, Bruce M Psaty1,4,7,8, Susan R Heckbert1,4, Dariush Mozaffarian9, Nona Sotoodehnia1. 1. Cardiovascular Health Research Unit, Department of Medicine (R.N.L., P.N.J., B.M.P., S.R.H., N.S.), University of Washington, Seattle. 2. Department of Laboratory Medicine (A.H.), University of Washington, Seattle. 3. Department of Biostatistics (B.M.), University of Washington, Seattle. 4. Department of Epidemiology (A.M.F., B.M.P., S.R.H.), University of Washington, Seattle. 5. Department of Internal Medicine, University of New Mexico, Albuquerque (I.B.K.). 6. New York Academy of Medicine, New York, NY (D.S.S.). 7. Department of Health Services (B.M.P.), University of Washington, Seattle. 8. Kaiser Permanente Washington Health Research Institute, Seattle, WA (B.M.P.). 9. Friedman School of Nutrition Science & Policy, Tufts University, Boston, MA (D.M.).
Abstract
BACKGROUND: Ceramides exhibit multiple biological activities that may influence the pathophysiology of heart failure. These activities may be influenced by the saturated fatty acid carried by the ceramide (Cer). However, the associations of different circulating Cer species, and their sphingomyelin (SM) precursors, with heart failure have received limited attention. METHODS AND RESULTS: We studied the associations of plasma Cer and SM species with incident heart failure in the Cardiovascular Health Study. We examined 8 species: Cer and SM with palmitic acid (Cer-16 and SM-16), species with arachidic acid (Cer-20 and SM-20), species with behenic acid (Cer-22 and SM-22), and species with lignoceric acid (Cer-24 and SM-24). During a median follow-up of 9.4 years, we identified 1179 cases of incident heart failure among 4249 study participants. In Cox regression analyses adjusted for risk factors, higher levels of Cer-16 and SM-16 were associated with higher risk of incident heart failure (hazard ratio for one SD increase:1.25 [95% CI, 1.16-1.36] and 1.28 [1.18-1.40], respectively). In contrast, higher levels of Cer-22 were associated with lower risk of heart failure in multivariable analyses further adjusted for Cer-16 (hazard ratio, 0.85 [0.78-0.92]); and higher levels of SM-20, SM-22 and SM-24 were associated with lower risk of heart failure in analyses further adjusted for SM-16 (hazard ratios, 0.83 [0.77-0.90], 0.81 [0.75-0.88], and 0.83 [0.77-0.90], respectively). No statistically significant interactions with age, sex, black race, body mass index, or baseline coronary heart disease were detected. Similar associations were observed for heart failure with preserved (n=529) or reduced (n=348) ejection fraction. CONCLUSIONS: This study shows associations of higher plasma levels of Cer-16 and SM-16 with increased risk of heart failure and higher levels of Cer-22, SM-20, SM-22, and SM-24 with decreased risk of heart failure. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00005133.
BACKGROUND:Ceramides exhibit multiple biological activities that may influence the pathophysiology of heart failure. These activities may be influenced by the saturated fatty acid carried by the ceramide (Cer). However, the associations of different circulating Cer species, and their sphingomyelin (SM) precursors, with heart failure have received limited attention. METHODS AND RESULTS: We studied the associations of plasma Cer and SM species with incident heart failure in the Cardiovascular Health Study. We examined 8 species: Cer and SM with palmitic acid (Cer-16 and SM-16), species with arachidic acid (Cer-20 and SM-20), species with behenic acid (Cer-22 and SM-22), and species with lignoceric acid (Cer-24 and SM-24). During a median follow-up of 9.4 years, we identified 1179 cases of incident heart failure among 4249 study participants. In Cox regression analyses adjusted for risk factors, higher levels of Cer-16 and SM-16 were associated with higher risk of incident heart failure (hazard ratio for one SD increase:1.25 [95% CI, 1.16-1.36] and 1.28 [1.18-1.40], respectively). In contrast, higher levels of Cer-22 were associated with lower risk of heart failure in multivariable analyses further adjusted for Cer-16 (hazard ratio, 0.85 [0.78-0.92]); and higher levels of SM-20, SM-22 and SM-24 were associated with lower risk of heart failure in analyses further adjusted for SM-16 (hazard ratios, 0.83 [0.77-0.90], 0.81 [0.75-0.88], and 0.83 [0.77-0.90], respectively). No statistically significant interactions with age, sex, black race, body mass index, or baseline coronary heart disease were detected. Similar associations were observed for heart failure with preserved (n=529) or reduced (n=348) ejection fraction. CONCLUSIONS: This study shows associations of higher plasma levels of Cer-16 and SM-16 with increased risk of heart failure and higher levels of Cer-22, SM-20, SM-22, and SM-24 with decreased risk of heart failure. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00005133.
Authors: J Eduardo Rame; Marlon Ramilo; Nali Spencer; Christopher Blewett; Sameer K Mehta; Daniel L Dries; Mark H Drazner Journal: Am J Cardiol Date: 2004-01-15 Impact factor: 2.778
Authors: J S Gottdiener; A M Arnold; G P Aurigemma; J F Polak; R P Tracy; D W Kitzman; J M Gardin; J E Rutledge; R C Boineau Journal: J Am Coll Cardiol Date: 2000-05 Impact factor: 24.094
Authors: Loek van Heerebeek; Attila Borbély; Hans W M Niessen; Jean G F Bronzwaer; Jolanda van der Velden; Ger J M Stienen; Wolfgang A Linke; Gerrit J Laarman; Walter J Paulus Journal: Circulation Date: 2006-04-17 Impact factor: 29.690
Authors: Amanda M Fretts; Paul N Jensen; Andrew N Hoofnagle; Barbara McKnight; Colleen M Sitlani; David S Siscovick; Irena B King; Bruce M Psaty; Nona Sotoodehnia; Rozenn N Lemaitre Journal: Clin Chem Date: 2021-11-26 Impact factor: 8.327
Authors: Rebekah J Nicholson; Marie K Norris; Annelise M Poss; William L Holland; Scott A Summers Journal: Annu Rev Nutr Date: 2022-05-18 Impact factor: 9.323
Authors: Jonathan J Petrocelli; Alec I McKenzie; Ziad S Mahmassani; Paul T Reidy; Gregory J Stoddard; Annelise M Poss; William L Holland; Scott A Summers; Micah J Drummond Journal: J Gerontol A Biol Sci Med Sci Date: 2020-09-16 Impact factor: 6.053
Authors: Amanda M Fretts; Paul N Jensen; Andrew Hoofnagle; Barbara McKnight; Barbara V Howard; Jason Umans; Chaoyu Yu; Colleen Sitlani; David S Siscovick; Irena B King; Nona Sotoodehnia; Rozenn N Lemaitre Journal: J Nutr Date: 2020-05-01 Impact factor: 4.798
Authors: Clemens Wittenbecher; Fabian Eichelmann; Estefanía Toledo; Marta Guasch-Ferré; Miguel Ruiz-Canela; Jun Li; Fernando Arós; Chih-Hao Lee; Liming Liang; Jordi Salas-Salvadó; Clary B Clish; Matthias B Schulze; Miguel Ángel Martínez-González; Frank B Hu Journal: Circ Res Date: 2020-12-04 Impact factor: 17.367
Authors: Sagar B Dugani; Luke R Christenson; Jeremiah A Aakre; Hai H Bui; Adrian Vella; Michelle M Mielke Journal: Diabetes Res Clin Pract Date: 2021-07-29 Impact factor: 8.180